Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
304.57+1.82 (+0.60%)
At close: 04:00PM EST
304.57 0.00 (0.00%)
After hours: 05:20PM EST
Advertisement
Sign in to post a message.
  • t
    thomas
    COULD SAMSUNG be looking for A DEVICE COMPANY???
    THAT HAS CASH AND EARNINGS.. ???
  • g
    gzkom
    326.94 +34.56 (+11.82%)
    After hours: 05:00PM EST, Jan. 18, 2022
  • t
    thomas
    What could have caused a one month move from

    $298 to ?????....
    Higher Lows and Higher Highs .. All while end of the year selling and Terrible
    economy.. ????
  • T
    Tommy
    so 4th run to 380 resistance? will this time break it or after ER?
  • T
    Tommy
    "1. First-in-human of Vortex, BSC new heart pump was successfully performed in three very high risk PCI cases. The pump worked flawlessly! 14F sheath but selfexpanding in-flow cannula allowing for improved flow compared to Impella CP"

    "Very stable position. No suction alarms, no need for purge/solution.
    Essential tool for complex high risk PCI..."

    From Twitter. Competition is coming. The Impella ECP must be as fast as possible avialable!
    Bearish
  • T
    Tommy
    rumour news: Buyout of SWAV (Shockwave)...maybe ABMD has the balls for a merger. ABMD need growth and SWAV has a lot of it. But has ABMD 10B Cash? NO! So a 100% stock deal possible? Or at the end as always the big boys (ABT, MDT, EW or BSX) is buying it :)
  • t
    thomas
    Very volitel the last week but ended positive.
    Hope it is company employee stock options selling
    due to expirations or year end profits..
    Has a $378 to $408 strong buy ..
  • B
    Binaya
    We, in the medical field use Impella all the time. No other device comes close to supporting an acutely injured heart. Usage in cardiac ICU an OR is increasing. Just a matter of time with new trial results earnings and stock will rise back to previous highs.
    Bullish
  • z
    zeus
    So unpredictable for a stock rated strong buy. Hard to believe this was trading 450 6 months ago
    Bearish
  • J
    JAD
    I believe there are also study results that show Impella much more favorable for patient outcomes than Balloon. Part of the problem possibly is proficiency of Users to deliver Impella correctly.
    But you are correct. Sale growth has slowed slightly. They have missed slightly on last 2 QTRs.
    The stock was arguably overpriced at $450. But sure seems to be oversold @ $165.
    Next QTR results are Key. Impella 5.5 may be a plus in guidance because that is coming online now or soon and has great potential
    Bullish
  • P
    Presifdsdsf
    FYI TO ALL. THE MAJOR DROP IN THE LAST WEEK IS DUE TO THE SHIFT IN MARKET RISKS AND RETURNS. HEDGE FUNDS ARE FAVORING MUCH HIGHER GROWTH COMPANIES LIKE MDB ZS AND OKTA VS SLOW GROWTH MED DEVICE INDUSTRY COMPANIES.
  • A
    Adrienne
    I’ve never seen a stock with solid fundamental (FDA approvals, respectable growth profile, sound financials) move like a broken stock... until ABMD. I am still averaging down. Gone this far with this stock (since 290s). I hope one of the bigger boys like Medtronic will acquire it. I dont see other way out. It has fallen despite every positive headlines.
    Bullish
  • J
    Jules
    Shorts are very stubborn on this stock. They have been trying to get it to $150 since the big drop months ago. The low daily average volume allows them to just kick back and control the trading price. This stock has made multiple failed attempts to get in the $200 range but every time it has some momentum, a re-print short article pops up to scare new buyers and attract more shorts. This stock just drip under $155 for the shorts to cover and move on.or big buyers on the ask for a few days keeps this over $225 and force them to cover.
    For now, it's a tight range between $175 and $196 until something changes it.
  • B
    Bill
    got back in and added a few shares at 250. I have been trading this stock for about 4 yrs. solid company that will work it way back up to $400. they have little competition and are at the top of their game.
  • T
    Todd
    I have owned shares of Abiomed at $18 and bought as high as $369 and back down to its current range of $176-$178. It has been painful to watch the stock fall from highs of $450; of course in hindsight I wish to have sold more shares on the way down. My optimism for buying on the way up was the product itself, Impella is one of the most innovative and significant devices in the Cardiovascular/Heart failure space today. I still feel the same about the device, but at these levels and a market cap around 8B Abiomed now presents itself as a viable buyout . At a 14-16B price tag Abiomed could be an attractive and very doable takeover for companies such as Abbott, who is building their Heart Failure space (acquisition of St Jude) or Phillips, who would benefit from integration of the Impella hardware in their cath lab systems (similar reason Siemens recently bought Corindus Vascular Robotics). In addition, Abiomed who be a great fit for Boston Scientific or Medtronic providing relevance to their coronary portfolios. Bottom line, if Abiomed continues to falter and management can not provide any confidence to the market and soon a buyout will be in their future.
    Bullish
  • V
    Vik
    From ZACK April 9, 19
    ABIOMED, Inc.engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company currently has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings increased 3.7% over the past 60 days. The company’s expected earnings growth rate for the current year is 106.1%, higher than the Medical - Instruments industry’s rise of 17.7%. The company has outperformed the broader industry in the past two-year period (+127.7% vs +37.4%).
    Bullish
  • J
    Jeff
    If read reports says news about China causing a withdrawal from healthcare stocks I feel there’s the cause , ride it out Abmd is solid I’ve been in it for years now from when they did the artificial heart transplants
  • P
    Presifdsdsf
    Ok. We know now what happened. Revenue growth has slowed greatly. But guidance is ok
  • Y
    Yah
    ABMD does not have a single Sell or even a Hold rating from any of the 11 analysts who cover the medical device maker, according to Bloomberg data, and the average price target of $435 is or more than 50% above the stock's $286 closing price today.
  • J
    Jake
    Am now officially up 200% on this stock.
Advertisement
Advertisement